Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

ANI Pharmaceuticals Announces an Agreement with Sofgen

Published: Friday, August 16, 2013
Last Updated: Friday, August 16, 2013
Bookmark and Share
Agreement for the development and marketing of an oral soft gel prescription product.

ANI Pharmaceuticals has announced that it has signed a binding letter of intent for the development of an oral soft gel prescription product with Sofgen Pharmaceuticals.

The product, indicated for cardiovascular health, will be the subject of an Abbreviated New Drug Application (“ANDA”) filing.

Sofgen will be responsible for the development, manufacturing and regulatory submission of the product and ANI will be responsible for marketing and distribution in the United States.

Arthur S. Przybyl, ANI’s President and CEO stated, “I am pleased to have entered into this collaboration with Sofgen for an oral soft gel drug. In addition to our internal product development efforts, we will continue to pursue opportunities through external partnerships and acquisitions in order to leverage our core capabilities in manufacturing and marketing. We are fortunate to have such a high quality partner in Sofgen.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ANI Pharmaceuticals to Acquire Two NDAs from Merck for $75 Million
Acquisition significantly advances ANI’s core strategy of re-commercializing previously approved products.
Friday, September 25, 2015
ANI Pharmaceuticals Acquires 22 Generic Drug Products
Company acquires drug products from Teva Pharmaceuticals for $25 million in cash.
Friday, July 17, 2015
ANI Pharmaceuticals Acquires 31 Generic Drug Products from Teva Pharmaceuticals
Company has acquired 31 marketed products for $12.5 million in cash.
Friday, January 03, 2014
ANI Acquires 31 Generic Drug Products from Teva
Previously marketed generic drug products were acquired for $12.5 million in cash and a percentage of future gross profits from product sales.
Friday, January 03, 2014
Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos